Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Cited by (1,002)

Items 901–1,000 of 1,002

1. T cell subtype profiling measures exhaustion and predicts anti-PD-1 response
   Ian Schillebeeckx, Jon Earls, Kevin C. Flanagan, Jeffrey Hiken, Alex Bode, Jon R. Armstrong, David N. Messina, Douglas R. Adkins, Jessica C. Ley, Ilaria Alborelli et al. · 2022 · Scientific Reports
2. Risk Signature Related to Immunotherapy Reaction of Hepatocellular Carcinoma Based on the Immune-Related Genes Associated With CD8+ T Cell Infiltration
   Yiping Zou, Zhihong Chen, Hongwei Han, Shiye Ruan, Liang Jin, Yuanpeng Zhang, Zhengrong Chen, Zuyi Ma, Qi Lou, Ning Shi et al. · 2021 · Frontiers in Molecular Biosciences
3. A unified cross-attention model for predicting antigen binding specificity to both HLA and TCR molecules
   Chenpeng Yu, Xing Fang, Shiye Tian, Hui Liu · 2025 · Nature Machine Intelligence
4. Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors
   Besan H. Al-Saafeen, Bassam R. Ali, Eyad Elkord · 2025 · Frontiers in Immunology
5. TRIM6 ablation reverses ICB resistance in MSS gastric cancer by unleashing cGAS-STING-dependent antitumor immunity
   Yinan Niu, Chen Ding, Quansheng Wang, Jingyi Yin, Lingmeng Li, Wenshuai Liu, Xuefei Wang, Liyu Huang · 2025 · Journal of Experimental & Clinical Cancer Research
6. Variable efficiency of nonsense-mediated mRNA decay across human tissues, tumors and individuals
   Guillermo Palou-Márquez, Fran Supek · 2025 · Genome biology
7. Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance
   Guang Lei, Zhengze Lu, Zhihao Xu, Chen Braun, David Huo, Jian Gao, Lin Tan, Ting Hong, Shengrong Wu, Mingchuang Sun et al. · 2026 · Cell
8. T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins
   Yixiang Xu, Georgina To’a Salazar, Ningyan Zhang, Zhiqiang An · 2019 · Antibody Therapeutics
9. Knowing the tumour microenvironment to optimise immunotherapy
   Marco Carlo Merlano, Andrea Abbona, Nerina Denaro, Ornella Garrone · 2019 · Acta Otorhinolaryngologica Italica
10. A B‐cell or a key player? The different roles of B‐cells and antibodies in melanoma
    Chloe B. Rodgers, Colette J. Mustard, Ryan Thomas McLean, S Hutchison, Antonia L. Pritchard · 2022 · Pigment Cell & Melanoma Research
11. Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade
    Gabriel Abril-Rodríguez, Davis Yuri Torrejon, Daniel Karin, Katie Marie Campbell, Egmidio Medina, Justin D. Saco, Mildred Galvez, Ameya S. Champhekar, Ivan Perez-Garcilazo, Ignacio Baselga-Carretero et al. · 2022 · Cancer Research Communications
12. Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden
    George Georgoulias, Apostolos Zaravinos · 2022 · Frontiers in Immunology
13. Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates
    Attila A. Seyhan, Claudio Carini · 2022 · International Journal of Molecular Sciences
14. TSC2 regulates tumor susceptibility to TRAIL‐mediated T‐cell killing by orchestrating mTOR signaling
    Chun‐Pu Lin, Joleen J.H. Traets, David W. Vredevoogd, Nils L. Visser, Daniel S. Peeper · 2023 · The EMBO Journal
15. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance
    B. Leticia Rodriguez, Limo Chen, Yanli Li, Shucheng Miao, David H. Peng, Jared J. Fradette, Lixia Diao, Jessica Marie Konen, Frank R. Rojas Alvarez, Luisa Maren Solis et al. · 2023 · Frontiers in Immunology
16. Unraveling tumor specific neoantigen immunogenicity prediction: a comprehensive analysis
    Guadalupe Nibeyro, Verónica M. Baronetto, Juan I. Folco, Pablo Pastore, María Romina Girotti, Laura Beatriz Prato, Gabriel Morón, Hugo Daniel Luján, Elmer A. Fernández · 2023 · Frontiers in Immunology
17. Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance
    Kun Chan Zheng, Youlong Hai, Yue Xi, Yukun Zhang, Zheqi Liu, Wantao Chen, Xiaoyong Hu, Xin Zou, Jie Hao · 2023 · Journal of Translational Medicine
18. Modulator of TMB-associated immune infiltration (MOTIF) predicts immunotherapy response and guides combination therapy
    Zheng-Yu Qian, Yi‐Qian Pan, Xuexin Li, Yan‐Xing Chen, Hao‐Xiang Wu, Zexian Liu, Martin Košař, Jiří Bártek, Zixian Wang, Rui‐Hua Xu · 2024 · 中国科学通报：英文版
19. PPP1R15A-expressing monocytic MDSCs promote immunosuppressive liver microenvironment in fibrosis-associated hepatocellular carcinoma
    Xiaoyu Liu, Man Liu, Haoran Wu, Wenshu Tang, Weiqin Yang, Thomas Ting-Hei Chan, Lingyun Zhang, Shufen Chen, Zhewen Xiong, Jianxin Liang et al. · 2024 · JHEP Reports
20. Acquired Resistance to Immune Checkpoint Blockade Therapies
    Xianda Zhao, Dechen Wangmo, Matthew J. Robertson, Subbaya Subramanian · 2020 · Cancers
21. Predicting immunotherapy response through genomics
    Marina Cândido Visontai Cormedi, Eliezer M. Van Allen, Leandro Machado Colli · 2020 · Current Opinion in Genetics & Development
22. DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor
    Chuan Wang, Nur Syafinaz Zainal, San Jiun Chai, James Dickie, Chai Phei Gan, Natasha Zulaziz, Bryan Kit Weng Lye, Ruhcha V. Sutavani, Christian H. H. Ottensmeier, Emma Victoria King et al. · 2021 · Frontiers in Immunology
23. A TCF4/BRD4-dependent regulatory network confers cross-resistance to targeted and immune checkpoint therapy in melanoma
    Joanna Poźniak, Dennis Pedri, Ewout Landeloos, Yannick Van Herck, Asier Antoranz, Panagiotis Karras, Ada Nowosad, Samira Makhzami, Greet Bervoets, Michael Dewaele et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
24. Identifying immune checkpoint-related lncRNA biomarkers for immunotherapy response and prognosis in cancers
    Yue Gao, Xinyue Wang, Longlong Dong, Changfan Qu, Qianyi Lu, Peng Wang, Mengyu Xin, Wen Zheng, Chenyu Liu, Shangwei Ning · 2023 · Scientific Data
25. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma
    Erina Takai, Wataru Omata, Yasushi Totoki, Hiromi K. Nakamura, Satoshi Shiba, Akira Takahashi, Kenjiro Namikawa, Taisuke Mori, Naoya Yamazaki, Tatsuhiro Shibata et al. · 2021 · Cancer Science
26. Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy
    Lindy Davis, Ashley Tarduno, Yong‐Chen Lu · 2021 · Cancers
27. Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors
    Deqiang Wang, Xiaofeng Chen, Yian Du, Xiaoqin Li, Leqian Ying, Yi Lü, Bo Shen, Xuan Gao, Xin Yi, Xuefeng Xia et al. · 2022 · Frontiers in Immunology
28. Characterization of Immune-Related Alternative Polyadenylation Events in Cancer Immunotherapy
    Gaoyang Wang, Zuozhong Xie, Juan Su, Meishan Chen, Yanhua Du, Qian Gao, Guanxiong Zhang, Hailun Zhang, Xiang Chen, Hong Liu et al. · 2022 · Cancer Research
29. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma
    Yi Luo, Hao Liu, Hong Yu Fu, Guoshan Ding, Fei Teng · 2022 · Frontiers in Immunology
30. Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions
    Enrico Sammarco, Fiorella Manfredi, Amedeo Nuzzo, Marco Ferrari, Adele Bonato, Alessia Salfi, Debora Serafin, Luca Zatteri, Andrea Antonuzzo, Luca Galli · 2023 · Cancers
31. Chromatin accessibility dynamics in colorectal cancer liver metastasis: Uncovering the liver tropism at single cell resolution
    Shasha Li, Ming Jen Yang, Shuaishuai Teng, Kequan Lin, Yumei Wang, Yanmei Zhang, Wei Guo, Dong Wang · 2023 · Pharmacological Research
32. Artificial intelligence learning landscape of triple-negative breast cancer uncovers new opportunities for enhancing outcomes and immunotherapy responses
    Shuyu Li, Nan Zhang, Hao Zhang, Ran Zhou, Zirui Li, Xue Yao Yang, Wantao Wu, Hanning Li, Peng Luo, Zeyu Wang et al. · 2023 · Journal Of Big Data
33. Complement and coagulation cascades pathway-related signature as a predictor of immunotherapy in metastatic urothelial cancer
    Zheng Gong, Yuming He, Xiao Mi, Chengcheng Li, Xiaoran Sun, Guoqiang Wang, Leo Li, Yusheng Han, Chunwei Xu, Wenxian Wang et al. · 2023 · Aging
34. Selective control of transposable element expression during T cell exhaustion and anti–PD-1 treatment
    Pierre‐Emmanuel Bonté, Christina Metoikidou, Sandrine Heurtebise-Chrétien, Yago A. Arribas, Aurélien Sutra Del Galy, Mengliang Ye, Leticia Laura Niborski, Elina Zueva, Eliane Piaggio, Agathe Seguin‐Givelet et al. · 2023 · Science Immunology
35. A Large-Scale Meta-Analysis Reveals Positive Feedback between Macrophages and T Cells That Sensitizes Tumors to Immunotherapy
    Jing Yang, Qi Liu, Yu Shyr · 2023 · Cancer Research
36. Integrating single-cell and bulk transcriptomic analyses to develop a cancer-associated fibroblast-derived biomarker for predicting prognosis and therapeutic response in breast cancer
    Chunzhen Li, Lanjie Yang, Yunyan Zhang, Qianshan Hou, Siyi Wang, Shaoteng Lu, Yijie Tao, Wei Hu, Liyuan Zhao · 2024 · Frontiers in Immunology
37. Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse
    Maria Effrosyni Livanou, Vasiliki Nikolaidou, Vasileios S. Skouras, Oraianthi Fiste, Elias Alexandros Kotteas · 2024 · Cancers
38. HLAIImaster: a deep learning method with adaptive domain knowledge predicts HLA II neoepitope immunogenic responses
    Qiang Yang, Long Xu, Weihe Dong, Xiaokun Li, Kuanquan Wang, Suyu Dong, Xianyu Zhang, Tiansong Yang, Feng Jiang, Bin Zhang et al. · 2024 · Briefings in Bioinformatics
39. Generation of cancer vaccine immunogens derived from major histocompatibility complex (MHC) class I molecules using variable epitope libraries
    Rodolfo Servín-Blanco, Rosa Mariana Chávaro-Ortiz, Rubén Zamora-Alvarado, Fernando Martínez‐Cortés, Goar Gevorkian, Karen Manoutcharian · 2018 · Immunology Letters
40. Prostate Cancer: Any Room Left for Immunotherapies?
    Constantin N. Baxevanis, Sotirios P. Fortis, Sonia A. Perez · 2019 · Immunotherapy
41. PD-1 aborts the activation trajectory of autoreactive CD8+ T cells to prohibit their acquisition of effector functions
    Hikari Okamura, Il‐mi Okazaki, Kenji Shimizu, Takumi Maruhashi, Daisuke Sugiura, Reina Mizuno, Taku Okazaki · 2019 · Journal of Autoimmunity
42. Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma
    Xubin Dong, Jingjing Song, Buran Chen, Yufeng Qi, Wenjie Jiang, Huihui Li, Danni Zheng, Yinghao Wang, Xiaohua Zhang, Haiguang Liu · 2021 · Frontiers in Oncology
43. The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications
    Kristian Michael Hargadon · 2021 · British Journal of Dermatology
44. Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling
    Joseph D. Butner, Geoffrey V. Martin, Zhihui Wang, Bruna Corradetti, Mauro Ferrari B, Nestor Esnaola, Caroline Chung, David S. Hong, James Welsh, Naomi Hasegawa et al. · 2021 · eLife
45. Neoantigen Controversies
    Andrea Castro, Maurizio Zanetti, Hannah K. Carter · 2021 · Annual Review of Biomedical Data Science
46. HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer
    Wenjing Zhang, Zhijuan Lin, Fuyan Shi, Qiang Wang, Yujia Kong, Yanfeng Ren, Juncheng Lyu, Chao Sheng, Yuting Li, Hao Qin et al. · 2022 · Cancers
47. Deciphering tertiary lymphoid structure heterogeneity reveals prognostic signature and therapeutic potentials for colorectal cancer: a multicenter retrospective cohort study
    Jia-Xin Lei, Runxian Wang, Chuling Hu, Xiaoying Lou, Min‐Yi Lv, Chenghang Li, Baowen Gai, Xiaojian Wu, Ruoxu Dou, Du Cai et al. · 2024 · International Journal of Surgery
48. Epithelium/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC
    Yongyuan Chen, Zheyu Shao, Zhixing Hao, Zhongwei Xin, Xiaoke Chen, Huang Lijian, Di Chen, Mingjie Lin, Qinyuan Liu, Xia Xu et al. · 2024 · Journal for ImmunoTherapy of Cancer
49. Integrating multi-omics and machine learning survival frameworks to build a prognostic model based on immune function and cell death patterns in a lung adenocarcinoma cohort
    Yiluo Xie, Huili Chen, Mei Tian, Ziqang Wang, Luyao Wang, Jing Zhang, Xiaojing Wang, Chaoqun Lian · 2024 · Frontiers in Immunology
50. Deciphering immune predictors of immunotherapy response: A multiomics approach at the pan-cancer level
    Xuexin Li, Lu Pan, Weiyuan Li, Bingyang Liu, Chunjie Xiao, Valerie Chew, Xuan Zhang, Long Wang, Florent Ginhoux, Joseph Loscalzo et al. · 2025 · Cell Reports Medicine
51. Targeting SIRT2 induces MLH1 deficiency and boosts antitumor immunity in preclinical colorectal cancer models
    Qianling Gao, Lanlan Yang, Shubiao Ye, Mingru Mai, Yiting Liu, Xuefei Jiang, Xingzhi Feng, Zihuan Yang · 2025 · Science Translational Medicine
52. Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy
    X. Li, Parham Jabbarzadeh Kaboli, Ghazaal Roozitalab, Shanli Salahi, Hongbo Qian, Xinyi Zhang, Keda Chen, Saber İmani · 2026 · Cellular Oncology
53. Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer
    Leonard H. Calabrese, Roberto Felice Caporali, Christian U. Blank, Allan D. Kirk · 2020 · Journal of Autoimmunity
54. Panels and models for accurate prediction of tumor mutation burden in tumor samples
    Elizabeth Martínez‐Pérez, Miguel Ángel Molina‐Vila, Cristina Marino‐Buslje · 2021 · npj Precision Oncology
55. Global Pattern of CD8+ T-Cell Infiltration and Exhaustion in Colorectal Cancer Predicts Cancer Immunotherapy Response
    Sun Tian, Fulong Wang, Rongxin Zhang, Gong Chen · 2021 · Frontiers in Pharmacology
56. Characterization of Aging-Related Genes to Predict Prognosis and Evaluate the Tumor Immune Microenvironment in Malignant Melanoma
    Ni Zeng, Chenrui Guo, Yajun Wang, Lin Li, Xi Chen, Shaoying Gao, Feng Jiang, Bilan Cao · 2022 · Journal of Oncology
57. Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer
    Ying Zuo, Jia Zhong, Hua Bai, Bin Xu, Zhijie Wang, Weihua Li, Yedan Chen, Shi Kun Jin, Shuhang Wang, Xin Wang et al. · 2022 · EBioMedicine
58. Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors
    Zhenzhen Liu, Yuzhu Diao, Xiaoling Li · 2022 · BMC Cancer
59. TMBcat: A multi-endpoint p-value criterion on different discrepancy metrics for superiorly inferring tumor mutation burden thresholds
    Yixuan Wang, Xin Lai, Jiayin Wang, Ying Xu, Xuanping Zhang, Xiaoyan Zhu, Yuqian Liu, Yang Washington Shao, Li Zhang, Wenfeng Fang · 2022 · Frontiers in Immunology
60. Evaluating the role of IDO1 macrophages in immunotherapy using scRNA-seq and bulk-seq in colorectal cancer
    Xingwu Liu, Guanyu Yan, Boyang Xu, Han Yu, Yue An, Mingjun Sun · 2022 · Frontiers in Immunology
61. Advances in the Lung Cancer Immunotherapy Approaches
    Hafiza Padinharayil, Reema Rose Alappat, Liji Maria Joy, Kavya V. Anilkumar, Cornelia M. Wilson, Alex George, Abilash Valsala Gopalakrishnan, Harishkumar Madhyastha, Thiyagarajan Ramesh, Ezhaveni Sathiyamoorthi et al. · 2022 · Vaccines
62. ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors
    Qiyi Yi, Youguang Pu, Fengmei Chao, Po Bian, Lei Lv · 2022 · Cancers
63. Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers
    Pavlina Spiliopoulou, Olga Vornicova, Sofia Genta, Anna Spreafico · 2023 · International Journal of Molecular Sciences
64. Large-Scale Immunopeptidome Analysis Reveals Recurrent Posttranslational Splicing of Cancer- and Immune-Associated Genes
    Ronen Levy, Tal Alter Regev, Wayne Paes, Nofar Gumpert, Sapir Cohen Shvefel, Osnat Bartok, Maria Dayan-Rubinov, Michal Alon, Merav D. Shmueli, Yishai Levin et al. · 2023 · Molecular & Cellular Proteomics
65. The therapeutic potential of targeting minimal residual disease in melanoma
    Riyaben P. Patel, Pretashini M Somasundram, Lorey K. Smith, Karen E. Sheppard, Grant A. McArthur · 2023 · Clinical and Translational Medicine
66. Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma—A multicenter real‐world experience in Israel
    Itamar Averbuch, Ronen Stoff, Mor Miodovnik, Shlomit Fenig, Gil Bar‐Sela, Alexander Yakobson, Jonathan Daliot, Nethanel Asher, Eyal Fenig · 2023 · Cancer Medicine
67. Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
    Aimilia Schina, Zsófia M. Sztupinszki, Inge Marie Svane, Zoltán Szállási, Goran B Jönsson, Marco Donia · 2023 · Journal for ImmunoTherapy of Cancer
68. Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours
    Arash Nabbi, Pengbo Beck, Alberto Delaidelli, Derek A. Oldridge, Sumedha Sudhaman, Kelsey Zhu, S.Y. Cindy Yang, David T. Mulder, Jeffrey P. Bruce, Joseph Nathaniel Paulson et al. · 2023 · Genome Medicine
69. Neoadjuvant personalized cancer vaccines: the final frontier?
    Guilhem Richard, Nicole Ruggiero, Gary D. Steinberg, William D Martin, Anne Searls De Groot · 2024 · Expert Review of Vaccines
70. Conserved methylation signatures associate with the tumor immune microenvironment and immunotherapy response
    Qingqing Qin, Ying Zhou, Jintao Guo, Qinwei Chen, Weiwei Tang, Yuchen Li, Jun You, Qiyuan Li · 2024 · Genome Medicine
71. Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios
    Gabriele Roccuzzo, Cristina Sarda, Valentina Pala, Simone Ribero, Pietro Quaglino · 2024 · Expert Review of Molecular Diagnostics
72. Genetic immune escape in cancer: timing and implications for treatment
    Francisco Martínez-Jiménez, Diego Chowell · 2024 · Trends in cancer
73. Cancer immunosurveillance by CD8 T cells
    José Carlos Crispín, George C. Tsokos · 2020 · F1000Research
74. Generation of multiepitope cancer vaccines based on large combinatorial libraries of survivin‐derived mutant epitopes
    Allan Noé Domínguez‐Romero, Fernando Martínez‐Cortés, María Elena Munguía, Josué Odales, Goar Gevorkian, Karen Manoutcharian · 2020 · Immunology
75. The head and neck cancer genome in the era of immunotherapy
    Neil Ari Wijetunga, Yao Yu, Luc G.T. Morris, Nancy Y. Lee, Nadeem Riaz · 2020 · Oral Oncology
76. Identification of an Individualized Immune-Related Prognostic Risk Score in Lung Squamous Cell Cancer
    Yuan Zhuang, Sihan Li, Chang Liu, Guang Li · 2021 · Frontiers in Oncology
77. Pan‐cancer analyses reveal that increased Hedgehog activity correlates with tumor immunosuppression and resistance to immune checkpoint inhibitors
    Junjie Jiang, Yongfeng Ding, Yanyan Chen, Jun Lü, Yiran Chen, Guanghao Wu, Nong Xu, Haiyong Wang, Lisong Teng · 2021 · Cancer Medicine
78. FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma
    Min M. Lu, Kaixuan Wang, Wenxiang Ji, Yongfeng Yu, Ziming Li, Weiliang Xia, Shun Lu · 2022 · Cellular Immunology
79. Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy (Review)
    Xiuyong Liao, Chaoyuan Liu, Jianfeng He, Li‐Shu Wang, Tao Zhang · 2019 · Oncology Letters
80. Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
    Małgorzata Bobrowicz, Radosław Zagożdżon, Joanna Domagała, Roberta Vasconcelos‐Berg, Emmanuella Guenova, Magdalena Winiarska · 2019 · Cancers
81. Transcriptomic Features of T Cell-Barren Tumors Are Conserved Across Diverse Tumor Types
    Eric D. Routh, Ashok Pullikuth, Guangxu Jin, Julia Chifman, Jeff W. Chou, Ralph B. D'Agostino, Ken‐ichiro Seino, Haruka Wada, Cristin Gregor Print, Wei Zhang et al. · 2020 · Frontiers in Immunology
82. Is tumor mutational burden predictive of response to immunotherapy?
    Carino Gurjao, Dina I. Tsukrov, Maxim Imakaev, Lovelace J. Luquette, Leonid A. Mirny · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
83. Prediction of immunotherapy responsiveness in melanoma through single-cell sequencing-based characterization of the tumor immune microenvironment
    Yucheng Dong, Zhizhuo Chen, Fan Yang, Jiaxin Wei, Jiuzuo Huang, Xiao Long · 2024 · Translational Oncology
84. Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction
    Xin Zhao, Bin Liu, William N. William, Kaloyan M. Tsanov, Yu-Jui Ho, Francisco M. Barriga, Raymond J. Lim, Maria Trifas, Azhar Khandekar, Yushen Du et al. · 2024 · Journal of Thoracic Oncology
85. Decoding melanoma’s cellular mosaic to unlock immunotherapy potential
    Joanna Poźniak, Jean‐Christophe Marine · 2025 · Trends in Cell Biology
86. Induced B cell receptor diversity predicts PD-1 blockade immunotherapy response
    Yonglu Che, Jinwoo Lee, Farah Abou-Taleb, Kerri E. Rieger, Ansuman T. Satpathy, Anne Lynn S. Chang, Howard Y. Chang · 2025 · Proceedings of the National Academy of Sciences
87. Senescent fibroblasts secrete CTHRC1 to promote cancer stemness in hepatocellular carcinoma
    Hai Huang, Wang Peng, Qiaodan Zhou, Yuchong Zhao, Luyao Liu, Haochen Cui, Jingwen Liang, Mengdie Cao, Wei Chen, Ronghua Wang et al. · 2025 · Cell Communication and Signaling
88. Comprehensive Analysis of m6A Regulators Characterized by the Immune Cell Infiltration in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy and Chemotherapy
    Zhiqiang Yang, Xiaoping Ming, Shuo Huang, Minlan Yang, Xuhong Zhou, Jiayu Fang · 2021 · Frontiers in Oncology
89. Quantification of Neoantigen-Mediated Immunoediting in Cancer Evolution
    Tao Wu, Guangshuai Wang, Xuan Wang, Shixiang Wang, Xiangyu Zhao, Chenxu Wu, Wei Ning, Ziyu Tao, Fuxiang Chen, Xue-Song Liu · 2022 · Cancer Research
90. Estimating tumor mutational burden from RNA-sequencing without a matched-normal sample
    Rotem Katzir, Noam Rudberg, Keren Yizhak · 2022 · Nature Communications
91. PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non‐small cell lung cancer
    Yiting Dong, Lele Zhao, Jianchun Duan, Hua Bai, Dongsheng Chen, Si Li, Yangyang Yu, Mingzhe Xiao, Qin Zhang, Qianqian Duan et al. · 2022 · Cell Proliferation
92. Targeting Tumor Hypoxia Inhibits Aggressive Phenotype of Dedifferentiated Thyroid Cancer
    Ben Ma, Shishuai Wen, Yi Luo, Ting-Ting Zhang, Yichen Yang, Cenkai Shen, Yan Zhang, Qinghai Ji, Ning Qu, Yu Wang · 2022 · The Journal of Clinical Endocrinology & Metabolism
93. Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma
    Xuenan Peng, Caifeng Gong, Wen Zhang, Aiping Zhou · 2023 · Frontiers in Oncology
94. The Effects of Clonal Heterogeneity on Cancer Immunosurveillance
    Krijn Kristian Dijkstra, Yin Wu, Charles Swanton · 2023 · Annual Review of Cancer Biology
95. Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype
    Kimberly Dessources, Lorenzo Ferrando, Qin C Zhou, Alexia E. Iasonos, Nadeem R. Abu‐Rustum, Jorge Sergio Reis-Filho, Nadeem Riaz, Dmitriy Zamarin, Britta Weigelt · 2023 · Gynecologic Oncology
96. Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy
    Joy Sarkar, Eduardo Cortes Gomez, Takaaki Oba, Hongbin Chen, Grace Kho Dy, Brahm H. Segal, Marc S. Ernstoff, Fumito Ito · 2023 · World Journal of Oncology
97. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
    Alberto Hernando‐Calvo, María Vila-Casadesús, Yacine Barèche, Alberto González‐Medina, Farnoosh Abbas Aghababazadeh, Deborah Lo Giacco, Ágatha Martín, Omar Saavedra, Irene Braña, María Vieito et al. · 2023 · Med
98. Tumor-infiltrating lymphocytes as a prognostic and predictive factor for Melanoma
    Gracia Maria Vargas, Neha Shafique, Xiaowei Xu, Giorgos Constantine Karakousis · 2024 · Expert Review of Molecular Diagnostics
99. A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor
    Mark D.M. Leiserson, Vasilis Syrgkanis, Amy Gilson, Miroslav Dudı́k, Sharon Gillett, Jennifer Chayes, Christian Borgs, Dean F. Bajorin, Jonathan E. Rosenberg, Samuel Aaron Funt et al. · 2018 · PLoS ONE
100. FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab
     Randy Yeh, Megan H. Trager, Emanuelle M. Rizk, Grace G. Finkel, Luke W. Barker, Richard D. Carvajal, Larisa J. Geskin, Gary K. Schwartz, Lawrence Howard Schwartz, Laurent Dercle et al. · 2020 · Clinical Nuclear Medicine